10-Q: Change Agents Corp. Reports Reduced Losses, Faces Going Concern Doubt

Change Agents Corporation (CHGA) filed its quarterly report for the period ended June 30, 2026, detailing a significant reduction in net loss but highlighting ongoing financial challenges and a substantial doubt about its ability to continue as a going concern.

Summary

• Change Agents Corporation (formerly Avalon GloboCare Corp.) reported a net loss of $2.18 million for the three months ended June 30, 2026, a significant improvement from $13.46 million in the same period last year.
• For the six months ended June 30, 2026, the net loss was $6.66 million, down from $15.94 million in the prior year.
• The company has a working capital deficit of approximately $4.09 million as of June 30, 2026.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern, citing recurring losses, negative cash flow, and insufficient cash to cover operating expenses for the next twelve months.
• The company plans to raise capital through equity sales to fund its business plan.
• The company is focusing on its AI software segment (Avalon Quantum AI) and its consumer health technology segment (Keto Air breathalyzer).
• Significant reductions in professional fees and advertising/marketing expenses contributed to the improved net loss.
• The company's common stock is subject to Nasdaq minimum bid price requirements, with a deadline to regain compliance by October 12, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's continued operating losses, significant working capital deficit, and substantial doubt about its ability to continue as a going concern, despite some operational expense reductions.

Positives

• Reduced net loss for both the three-month period ($2.18M vs $13.46M) and the six-month period ($6.66M vs $15.94M) compared to the prior year.
• Significant decrease in professional fees by 44.3% for the quarter and 22.3% for the six months.
• Reduction in advertising and marketing expenses by 67.4% for the quarter and 20.0% for the six months.
• The company has a new AI software segment focused on video generation and search optimization.
• The company is actively seeking complementary AI acquisitions.
• The company has a consumer health technology segment distributing the Keto Air breathalyzer.

Negatives

• The company has a working capital deficit of $4.09 million as of June 30, 2026.
• Management has identified substantial doubt about the company's ability to continue as a going concern.
• The company incurred a net loss of $2.18 million in the latest quarter and $6.66 million year-to-date.
• Cash balance of $39,221 at June 30, 2026, is insufficient to cover operating expenses for the next twelve months.
• The company's common stock is at risk of delisting from Nasdaq due to not meeting the minimum bid price requirement, with a compliance deadline of October 12, 2026.
• The company has suspended research and development efforts related to cellular therapy to preserve cash.

Risks

• Failure to regain compliance with Nasdaq minimum bid price requirements could lead to delisting, adversely affecting stock liquidity and the ability to obtain financing.
• The company's ability to continue as a going concern is dependent on raising additional capital, implementing its business plan, and generating sufficient revenues.
• The company's limited operating history and recurring losses raise concerns about its long-term viability.
• The company's cash balance is insufficient to cover operating expenses for the next twelve months, necessitating future financing.
• The company's new AI initiatives require significant investment and market adoption.
• The company's consumer health product (Keto Air) distribution rights in North America are through July 2025, with future distribution uncertain.
• The company has material weaknesses in internal control over financial reporting related to segregation of duties and testing of control effectiveness.

Future Outlook

The company expects its advertising and marketing expenses to remain at current levels with minimal increase. Compensation and related benefits are expected to decrease in the near future. The company anticipates an increase in cash used in operating activities due to development and commercialization of new products and increased marketing efforts. Future operations are dependent on securing additional financing.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• The company plans on raising capital through the sale of equity to implement its business plan.
• Management expects that their professional fees will decrease in the near future.
• Management expects that their compensation and related benefits will likely decrease in the near future.

Industry Context

StockSavvy.ai notes that the company's strategic shift towards AI software, particularly in video generation and search optimization, aligns with broader industry trends. However, the consumer health technology segment, while present, appears to be a smaller focus compared to the AI initiatives.

Comparison to Industry Standards

• The company's net loss of $6.66 million for the first six months of 2026, while reduced from the previous year, is still substantial for a company with limited revenue streams from its new AI ventures.
• The significant reduction in professional fees suggests cost-cutting measures, which is common for companies in early-stage development or facing financial challenges.
• The company's reliance on future financing to continue operations is a common characteristic of many early-stage technology companies, but the explicit mention of 'substantial doubt about its ability to continue as a going concern' is a critical indicator of financial distress.

Legal Proceedings

• The company is subject to ordinary routine litigation incidental to its normal business operations, but is not currently a party to any material legal proceedings that would have a material adverse effect.

Related Party Transactions

• Sale of Avalon RT 9 subsidiary to Wenzhao Lu, the Company's chairman of the Board of Directors, for $9.0 million.
• The company leases office space from Avalon RT 9, which is wholly owned by Wenzhao Lu.
• Consulting services were provided by Wilbert Tauzin, a former director, and his son.
• An unpaid acquisition consideration of $100,000 was payable to Dr. Yu Zhou, former director and former co-chief executive officer.

Stakeholder Impact

• Shareholders face continued risk due to the company's going concern issues and potential Nasdaq delisting.
• Employees may be impacted by the company's financial instability and potential need for further cost-cutting measures.
• Creditors and lenders may face increased risk given the company's liquidity challenges and reliance on future financing.

Next Steps

• Regain compliance with Nasdaq minimum bid price requirements by October 12, 2026.
• Continue development of the Phase 2 Catch-Up AI-powered Video Platform, expected to launch in Q3 2026.
• Seek complementary bolt-on AI acquisitions.
• Raise additional capital to fund operations and working capital needs.

Key Dates

Recommendation

The company's financial condition, characterized by significant losses, a working capital deficit, and explicit statements of doubt regarding its ability to continue as a going concern, presents a high level of risk. The potential delisting from Nasdaq further exacerbates these concerns. While the company is pursuing new AI ventures, the immediate financial instability outweighs the potential future benefits, making it a speculative investment with a high probability of further downside.

Keywords

AI software, Agentic AI, video generation, Keto Air, breathalyzer, going concern, Nasdaq compliance, financial results